The heartbeat of cardiovascular medicine and telemedicine

Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment

Sponsored
Message: CardioComm Solutions Launches 12-Lead ECG Smart Wearable Garment Monitoring Solution

Joint marketing efforts by CardioComm Solutions and HealthWatch Technologies will target cardiac monitoring markets in the USA and Europe

Toronto, Ontario--(October 30, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today announced its joint partnership sales plans for the commercial launch of its newest software release designed to support an innovative and easy to use wireless, 12 lead ECG, vital signs, arrhythmia and ischemia monitoring wearable smart garment manufactured by Israel-based HealthWatch Technologies Ltd. ("HealthWatch").

The two companies began co-development efforts last year to bring to market an FDA-cleared (USA sales) and CE-approved (European sales) easy to use remote 12- lead monitoring, ECG wearable smart garment solution. In June 2017, the companies confirmed they were awarded a grant through the Canadian-Israeli Industrial R&D Foundation ("CIIRDF") to fast-track their development efforts. In September of 2018, the companies executed a co-marketing agreement that would expand their sales and marketing scope for this unique wearable ECG monitoring solution to include sales into Europe.

With CardioComm's completion of software and hardware quality system documentation, the companies have a green light for the sales launch of the wearable, remote ECG monitoring technology. HealthWatch will leverage a large number of pre-scheduled sales and marketing meetings during Medica, Europe's largest medical exposition, to deliver a very strong marketing message. Following Medica, both companies will collaborate to launch the solution to CardioComm's current USA based GEMS™ WIN accounts who will be able to include use of the Master Caution® garment to their current GEMS™ WIN license without the need to add new management software and/or learn new workflows.

The companies will focus marketing efforts on groups active in mobile cardiac telemetry services, arrhythmia and prolonged QT interval screening, ECG monitoring as an extension to in-hospital/clinic services, and to those involved in providing long-term managed care support for people living with chronic medical conditions. Both GEMS™ WIN and GEMS™ Flex applications are scalable and can support enterprise applications to concurrently monitor very high patient volumes. The new wearable/software ECG monitoring product is a superior solution over the ECG recording products typically used today with patches, straps, electrodes and/or cables. The new solution is also perfectly suited for athletes and sports enthusiasts who routinely monitor their ECGs thereby opening up new markets for CardioComm and HealthWatch.

To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

About HealthWatch

HealthWatch was founded in 2010 in Kfar Saba, Israel, and has developed the Master Caution®, the first and only 3-12-lead ECG smart digital garment that is CE/FDA-cleared. It advocates a full management solution for the purpose of transforming healthcare, offering a digital health platform and virtual medical care intertwined with the Medical Internet-of-Things. This non-lifestyle changing disruptive technology, based on wearable textile-electrodes and heart-sensing sensors and technologies, contains a myriad of accurate digital health diagnostic services including mobile cardiac telemetry, patient monitoring tele-health services and other services that allow for in-home medical services. The Master Caution®'s continuous monitoring solutions assist clinicians in remotely monitoring their elderly or bed-ridden patients, while being alerted to cardiac events such as ischemia and arrhythmias in near real-time, securing personal health around-the-clock for improved patient safety.

FOR FURTHER INFORMATION PLEASE CONTACT:
Moran Faibish, Marketing Manager
[email protected]
www.healthwatchtech.com

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share
New Message
Please login to post a reply